GLP-1s Linked to Lower Fragility Fracture Risk in Diabetes

Initiating GLP-1 receptor agonists for type 2 diabetes was associated with a reduced risk of fragility fractures in adults aged 50 and older, including hip and vertebral fractures. This finding comes from a large target trial emulation study published in JAMA Network Open.

The study analyzed data from 150,000 individuals with type 2 diabetes, comparing those who started a GLP-1 receptor agonist with those who initiated other diabetes medications. The researchers found a 17% lower risk of any fragility fracture among GLP-1 receptor agonist users. Specifically, the risk of hip fractures decreased by 20%, and vertebral fractures by 26%.

These results suggest a potential benefit of GLP-1 receptor agonists beyond glycemic control and weight loss, offering a protective effect against bone-related injuries. Fragility fractures are a significant cause of morbidity and mortality in older adults, particularly those with diabetes, who are already at an increased risk.

The study's authors noted that while the mechanisms are not fully elucidated, potential pathways include improved bone quality, reduced falls due to better glycemic control and balance, or direct effects on bone metabolism. Further research is warranted to confirm these findings and explore the underlying biological processes. The study's design aimed to mimic a randomized controlled trial, strengthening the evidence for this association.